Subsidy Information and Financing Scheme MSHLEncorafenib Capsule 75 mg Encorafenib in combination with cetuximab for the treatment of patients with metastatic colorectal ... See all × MSHLEncorafenib Capsule 75 mg Encorafenib in combination with cetuximab for the treatment of patients with metastatic colorectal cancer with a BRAF V600E mutation, who have received prior systemic therapy.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Capsule 75 mg National Cancer Centre
ORAL Select a brand starting with the letter: B BRAFTOVI HARD CAPSULE 50MG [SIN16825P] BRAFTOVI HARD CAPSULE 75MG [SIN16824P]